The ImmuBridge™ platform embodies cutting-edge advancements in oncology and immunotherapy. Leveraging this platform, we can develop trispecific antibodies targeting a variety of immune and tumor cell antigens to activate diverse immune mechanisms, fostering precise and efficient cancer therapeutics.
